Cargando…

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children

PURPOSE: This study was conducted to determine the effect of UGT1A9 98T>C, CYP2B6 516G>T and CYP2C9 430C>T genetic polymorphisms on the pharmacokinetics of propofol in children of different sexes and ages who undergone total intravenous anesthesia (ТIVA) and deep sedation during diagnostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pavlovic, Dimitrije, Budic, Ivana, Jevtovic Stoimenov, Tatjana, Stokanovic, Dragana, Marjanovic, Vesna, Stevic, Marija, Slavkovic, Milan, Simic, Dusica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974130/ https://www.ncbi.nlm.nih.gov/pubmed/32021384 http://dx.doi.org/10.2147/PGPM.S231329

Ejemplares similares

Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics
por: Budic, Ivana, et al.
Publicado: (2022)

The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia
por: Mikstacki, Adam, et al.
Publicado: (2016)

Association between Galectin-3 levels within central and peripheral venous blood, and adverse left ventricular remodelling after first acute myocardial infarction
por: Andrejic, Olivera M., et al.
Publicado: (2019)

Evaluation of factors for poor outcome in preterm newborns with posthemorrhagic hydrocephalus associated with late-onset neonatal sepsis
por: Stevic, Marija, et al.
Publicado: (2018)

Effect of sex and polymorphisms of CYP2B6 and UGT1A9 on the difference between the target-controlled infusion predicted and measured plasma propofol concentration
por: Fujita, Ai, et al.
Publicado: (2018)

Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure
por: Vucic, Rada M., et al.
Publicado: (2023)

Functional characterization of the defective CYP2C9 variant CYP2C9*18
por: Liu, Jian, et al.
Publicado: (2021)

Effect of the Interrelation between CYP3A5 Genotype, Concentration/Dose Ratio and Intrapatient Variability of Tacrolimus on Kidney Graft Function: Monte Carlo Simulation Approach
por: Stefanović, Nikola, et al.
Publicado: (2021)

The Association between Galectin-3 and hs-CRP and the Clinical Outcome after Non-ST-Elevation Myocardial Infarction with Preexisting Atrial Fibrillation
por: Pavlović, Milan, et al.
Publicado: (2017)

Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria
por: Palikhe, Nami Shrestha, et al.
Publicado: (2011)

Management of Anesthesia in a Child with a Large Neck Rhabdoid Tumor
por: Stevic, Marija, et al.
Publicado: (2016)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients
por: Krall, Paola, et al.
Publicado: (2021)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol
por: Cho, Pil Joung, et al.
Publicado: (2018)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers
por: Borrego-Soto, Gissela, et al.
Publicado: (2020)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
por: Johansson, Maria, et al.
Publicado: (2014)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
por: Yasar, Umit
Publicado: (2018)

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
por: Schmidt, R, et al.
Publicado: (2004)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity
por: Rodríguez-Morató, Jose, et al.
Publicado: (2019)

Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
por: Tang, Peng-fei, et al.
Publicado: (2020)

Association of CYP2C9 Genetic Variants with Vitiligo
por: Alzolibani, Abdullateef A., et al.
Publicado: (2014)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

Relevance of CYP2C9 Function in Valproate Therapy
por: Monostory, Katalin, et al.
Publicado: (2019)

Oxidant and Antioxidant Status in Experimental Rat Testis after Testicular Torsion/Detorsion
por: Cvetkovic, Tatjana, et al.
Publicado: (2015)

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population
por: Zhao, Fang-Ling, et al.
Publicado: (2022)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
por: Jovanović, Nikola, et al.
Publicado: (2019)

The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals
por: Haeggström, Sigrid, et al.
Publicado: (2022)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
por: Xiao, Jim J., et al.
Publicado: (2018)

Distribution of MEFV gene mutations and R202Q polymorphism in the Serbian population and their influence on oxidative stress and clinical manifestations of inflammation
por: Milenković, Jelena, et al.
Publicado: (2016)

Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy
por: Lakhan, Ram, et al.
Publicado: (2011)

CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
por: Zhang, Lingxin, et al.
Publicado: (2020)

Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
por: Swart, Marelize, et al.
Publicado: (2014)

Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana
por: Alvarado, Ángel Tito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jf0l16bum2cif65gt4bdvcs749